13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2012-005113-39-AT (EUCTR) | 08/04/2013 | 18/02/2013 | Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve. | A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis - Amiloride Hydrochlorothiazide in acute autoimmune optic neuritis | Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Amilostad HCT Product Name: Amilostad HCT tablets INN or Proposed INN: AMILORIDE HYDROCHLORIDE, 2 H2O Other descriptive name: Amiloride Hydrochloride INN or Proposed INN: hydrochlorothiazide Other descriptive name: HYDROCHLOROTHIAZIDE | Universitätsklinik für Neurologie, Medizinische Universität Wien | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Austria | |||
2 | EUCTR2007-004051-11-GB (EUCTR) | 18/12/2008 | 15/07/2008 | Amiloride Treatment in Multiple Sclerosis - Amiloride in MS | Amiloride Treatment in Multiple Sclerosis - Amiloride in MS | Multiple Sclerosis | Trade Name: Amiloride Product Name: Amiloride Hydrochloride | Oxford Racliffe NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | 23 | United Kingdom |